Limaprost

Limaprost, also known as ONO 1206 and OP1206, is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency. Limaprost is orally active. Limaprost reduces motor disturbances by increasing the production of insulin-like growth factor I in rats subjected to spinal cord injury.

Product information

CAS Number: 74397-12-9

Molecular Weight: 380.52

Formula: C22H36O5

Synonym:

17α,20-dimethyl-δ2-PGE1

ONO1206

OP1206

Chemical Name: (2E)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl]hept-2-enoic acid

Smiles: C[C@H](C[C@H](O)/C=C/[C@@H]1[C@@H](CCCC/C=C/C(O)=O)C(=O)C[C@H]1O)CCCC

InChiKey: OJZYRQPMEIEQFC-UAWLTFRCSA-N

InChi: InChI=1S/C22H36O5/c1-3-4-9-16(2)14-17(23)12-13-19-18(20(24)15-21(19)25)10-7-5-6-8-11-22(26)27/h8,11-13,16-19,21,23,25H,3-7,9-10,14-15H2,1-2H3,(H,26,27)/b11-8+,13-12+/t16-,17+,18+,19+,21+/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 40 mg/mL (105.12 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Limaprost inhibits the IL-1-mediated induction of nerve growth factor (NGF) in a concentration-dependent manner with an IC50 value of 70.9  nM human IVD cells.

In Vivo:

Limaprost (OP1206) given orally at more than 100 μg/kg relieves Argipressin-induced ST depression of rat electrocardiogram (ECG). Intra-coronary injection of Limaprost (OP1206; 1-100 ng/kg) in dogs results in a remarkable increase of coronary blood flow without any influence on heart rate, blood pressure, myocardial oxygen consumption and redox potential. Resistance in both large and small vessels of dog coronary artery is decreased by intravenous injection of Limaprost (OP1206; 1-3 mg/kg). Platelet aggregation, adhesiveness, bleeding time, and thrombocytopenia induced by ADP and collagen infusion in guinea-pigs are inhibited by oral administration of Limaprost (OP1206) at the same doses or doses less than those relieving Argipressin-induced ST depression of ECG.

References:

1. Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):89-102.
2. Swainston Harrison T, et al. Limaprost. Drugs. 2007;67(1):109-18; discussion 119-20.

Products are for research use only. Not for human use.